Apimeds Pharmaceuticals US, Inc.
APUS
Analytical Summary
Apimeds Pharmaceuticals US, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.
4-Year Financial Trajectory
AnnualHealth Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| EPS Growth YoY (%) |
-205.6%
Weak
Weak
Year-over-year change in earnings per share
Optimal:
> 10%
|
-5.9%
Weak
Weak
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — |
| Net Income Growth YoY (%) |
-331.7%
Weak
Weak
Year-over-year change in net income |
-78.7%
Weak
Weak
Year-over-year change in net income |
— | — |
| FCF Growth YoY (%) |
-789.5%
Weak
Weak
Year-over-year change in free cash flow |
32.0%
Excellent
Excellent
Year-over-year change in free cash flow |
— | — |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| FCF / Net Income (x) |
1.50x
Good
↑
Good
Improving
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.53x
Weak
Weak
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.81x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Return on Invested Capital (%) |
-6.1%
Weak
↑
Weak
Improving
Return earned on debt + equity capital invested
Optimal:
> 10%
|
74.2%
Excellent
Excellent
Return earned on debt + equity capital invested
Optimal:
> 10%
|
-1852.8%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
| Return on Capital (%) (%) |
-7.3%
Weak
↑
Weak
Improving
Operating profit relative to total assets
Optimal:
> 10%
|
-9765.6%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
-177.1%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— |
| Return on Common Equity (%) (%) |
-3.9%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-126%)
|
102.3%
Excellent
Excellent
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+582%)
|
— | — |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Debt to Equity (x) | — |
-0.01x
Excellent
Excellent
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-102%)
|
— | — |
| Net Debt (USD) | $-1.64M | $16.55K | $-410.48K | — |
| Debt / EBITDA (x) | — |
-0.02x
Excellent
Excellent
Debt relative to earnings before interest, taxes, depreciation
Optimal:
< 2x
|
— | — |
Secondary lens
Benchmark Lens
Compare APUS against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare APUS against peers after checking the statement evidence.
Percentile Rankings
How APUS compares to all companies
Peer Comparison
APUS vs similar peers
Compare APUS with peers
Stack APUS against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced yesterday 4 years · 12 quarters